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Abstract
Ulcerative colitis (UC) is a chronic inflammatory 
condition affecting the large bowel and is associated 
with a significant risk of both requirement for surgery 
and the need for hospitalisation. Thiopurines, and 
more recently, anti-tumour necrosis factor (aTNF) 
therapy have been used successfully to induce clinical 
remission. However, there is less data available on 
whether these agents prevent long-term colectomy 
rates or the need for hospitalisation. The focus of this 
article is to review the recent and pertinent literature 
on the long-term impact of thiopurines and aTNF on 
long-term surgical and hospitalisation rates in UC. Data 
from population based longitudinal research indicates 
that thiopurine therapy probably has a protective role 
against colectomy, if used in appropriate patients for a 
sufficient duration. aTNF agents appear to have a short 
term protective effect against colectomy, but data is 
limited for longer periods. Whereas there is insufficient 
evidence that thiopurines affect hospitalisation, evidence 
favours that aTNF therapy probably reduces the risk 
of hospitalisation within the first year of use, but it is 
less clear on whether this effect continues beyond this 
period. More structured research needs to be conducted 
to answer these clinically important questions.
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Core tip: Longitudinal population data indicates a 
protective effect of thiopurines on colectomy in 
ulcerative colitis in the long-term, but there is limited 
evidence that they reduce hospitalisation. Research on 
anti-tumour necrosis factor therapy shows a possible 
short-term protective effect against colectomy, but 
more data is needed to address any long-term benefits.
Alexakis C, Pollok RCG. Impact of thiopurines and anti­
tumour necrosis factor therapy on hospitalisation and long­
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INTRODUCTION
Ulcerative colitis (UC) is a chronic relapsing and 
remitting bowel condition that presents with recurrent 
episodes of colonic inflammation, manifesting as per­
iods of prolonged bloody diarrhoea. Despite advances 
in pharmacological therapies for UC, there is still no 
known medical cure, and the condition is associated 
with a considerable risk of surgery[1]. Moreover, the 
disease process is often associated with the need 
for hospitalisation, usually during acute flares. Hospi­
talisation has been correlated with lower health related 
quality of life in inflammatory bowel disease (IBD) 
patients[2], and is possibly the most costly aspect for 
healthcare providers in the long­term management of 
patients with IBD[3]. As both hospitalization and surgery 
are objectively identifiable and clinically important events 
in the natural history of UC, they make attractive clinical 
endpoints, particularly when addressing the efficacy of 
UC specific drugs.
The first clinical trials assessing thiopurines in UC 
are over thirty years old[4], but these drugs [including 
azathioprine (AZA) and 6­mercaptopurine (6MP)] are 
now established as effective steroid sparing agents in 
the maintenance of remission in UC, and are advocated 
in national and international guidelines[5­7]. Over the past 
decade, the use of anti­tumour necrosis factors (aTNF), 
including infliximab and adalimumab, has impacted 
greatly on the management Crohn’s disease, and more 
recently in UC[8,9] but their role in altering long­term 
outcomes, in particular surgery and hospitalisation, is 
less well characterised.
This review focuses on the impact of thiopurines 
and aTNF therapy on long­term surgical outcomes 
and hospitalisation in patients with UC. The definition 
of “long­term” is not easily quantifiable, but for the 
purposes of the review, we will be primarily considering 
research that focuses on these two outcomes at one 
year or later from pharmacological intervention. 
SURGERY
Requirement for colectomy is a key endpoint in UC. 
Some evidence suggests colectomy rates are de­
creasing. In a large European cohort studied over 30 
years, the cumulative probability of surgery at 9 years 
in UC fell from 14.5% in patients diagnosed between 
1979­1986 to 9.1% in patients diagnosed between 
2003­2011[10]. A recent systematic review and meta­
analysis indicated that colectomy rates within 10 years 
of diagnosis have decreased over the past 20 years, 
with an estimated 10 year risk of colectomy in UC of 
approximately 15%[1]. However, the risk of colectomy 
within 5 years of diagnosis has not changed significantly 
over the past 20 years raising a question about the 
efficacy of contemporary medical management in alter­
ing the overall risk of colectomy in the first 5 years of 
diagnosis, particularly amongst patients with an early 
onset severe disease phenotype.
It is thus important to try and gauge the impact 
of both thiopurines and aTNF in long­term surgical 
outcomes. Table 1 summarises the key literature with 
regards to both thiopurines and aTNF and their impact 
on surgical outcomes.
Thiopurines and long-term surgical outcomes
Data from randomised clinical trials addressing risk of 
surgery and efficacy of thiopurines is limited. Early trials 
reported conflicting results, but were limited by small 
patient numbers[4,11]. 
A recent Cochrane review comparing AZA or 6MP vs 
placebo or best treatment in patients with UC included 
only 6 randomised controlled trials (RCT). Although the 
review strongly favoured AZA use for achieving clinical 
remission, long­term colectomy was not considered as 
a measured endpoint[12].
A number of large population based studies have 
attempted to quantify the impact of immuno­modula­
tors on surgery in UC, with more encouraging findings. 
Kaplan et al[13] reported a population time trends 
analysis on colectomy rates in a Canadian cohort of 
UC patients between 1997 and 2009. Over the study 
period, there was a clear reduction in elective colectomy 
rates by 7.4% per year, but rates for emergency pro­
cedures remained static. Over the same period, the 
authors reported a doubling of thiopurine usage but 
were cautious about making inferences about any 
trend given the absence of a clear inflection point bet­
ween increased immuno­modulator use and reduced 
colectomy rates. In a large Canadian population based 
study from Manitoba including 3752 UC patients with 
up to 25 years of follow up, a colectomy rate of 10.4% 
at 10 years was reported[14]. Almost quarter of the 
cohort exposed to immuno­modulator had undergone 
colectomy by 5 years. In a sub­analysis of thiopurine 
users, patients exposed to more than 16 wk of therapy 
had a significantly decreased colectomy rate at 2 years 
(5.6% vs 12.8%), although immuno­modulator use 
was not included in the final logistic regression analysis 
calculating risk of early or late colectomy. Similarly, a 
large Danish registry study of IBD patients showed a 
reduction in colectomy rates in patients with UC over 
the 32 year study period. This decrease was in parallel 
with a significant increase in thiopurine use, although 
regression analysis did not indicate a significant 
protective effect of thiopurine exposure on colectomy[10].
The potential value of prolonged thiopurine exposure 
was further evaluated by Chhaya et al[15] in a United 
Kingdom population based cohort study of 8673 patients 
with UC between 1989 and 2009. After adjusting for 
confounding factors, the authors found no significant fall 
in colectomy rates within 5 years of diagnosis during the 
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20 year study period. Also, requirement for thiopurines 
defined a group of patients with an associated higher 
risk of colectomy[15]. Amongst patients treated with 
thiopurines, use for greater than 12 mo (compared to 
use ≤ 3 mo) was associated with a significant reduction 
in requirement for colectomy by end of follow up (HR 
= 0.29, 95%CI: 0.21­0.40). But, early thiopurine use 
(defined as within 1 year of diagnosis of UC) added 
no additional reduction suggesting some patients with 
early onset severe disease were either refractory to 
thiopurines or had insufficient time to benefit from 
these drugs before surgery was required.
Most recently, Cañas­Ventura et al[16] described 
colectomy rates and risk factors for colectomy in a 
cohort of 1334 Spanish UC patients drawn from a 
national IBD registry. All patients had had a minimum 
exposure to immuno­modulator therapy (AZA at 
median dose of 150 mg/d or 6­mercaptopurine at a 
median dose of 75 mg/d) of at least 3 mo. The 5 years 
cumulative risk of colectomy for the cohort was 8.8%, 
and regression analysis demonstrated an increased risk 
of colectomy in patients receiving immuno­modulator 
therapy within the first 33 mo of diagnosis vs those 
started after this time (HR = 4.9, 95%CI: 3.2­7.8). 
Data from “real world” single centre retrospective 
studies are limited and conflicting in their reporting of 
the effect of thiopurine therapy on surgery. Williet et 
al[17] reported medication usage in 151 unselected UC 
patients (median follow up 58 mo) and their subsequent 
risk of needing colectomy. In this study, exposure 
to thiopurine therapy was not associated with an 
increased risk of colectomy risk in regression analysis. 
In contrast, data from a Japanese single centre study of 
222 UC patients followed for up to 11 years indicated a 
significant protective effect of thiopurine treatment on 
colectomy (HR = 0.2, 95%CI: 0.08­0.67), although the 
sub­analysis only included hospitalised patients[18].
In summary, there is limited data from prospective 
controlled trials and retrospective observational studies 
to support a protective effect of thiopurine therapy in 
reducing the overall risk of colectomy. This is inherently 
related to the design of most studies that focus on non­
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Table 1  Summary of key research investigating impact of thiopurines and tumour necrosis factor inhibitors therapy on long-term 
surgical outcomes in ulcerative colitis
Ref. Study design Population n Key findings
Thiopurines Ardizzone et al[11] RCT comparing AZA vs 
5-ASA
Steroid dependent 
UC
    72 No difference in colectomy rates at 6 mo between AZA and 
5-ASA groups
Kaplan et al[13] Population based time 
trends analysis of colectomy 
rates
Unselected UC N/A Reduction in elective colectomy rates of 7.4% per year
Doubling of TP use over the study period
Emergency colectomy rates remain static
Targownik et al[14] Population based analysis 
of colectomy rates
Unselected UC 3752 10.4% colectomy rate at 10 yr post diagnosis
> 16 wk TP therapy associated with reduced colectomy 
requirement
Chhaya et al[15] Population based time 
trends analysis of colectomy 
rates
Unselected UC 8673 TP use > 12 mo associated with a 71% reduction in risk of 
colectomy
Early TP use not associated with added benefit
No significant change in colectomy rates over study period 
Cañas-Ventura et al[16] Retrospective descriptive 
cohort study of UC patients 
receiving AZA
Unselected UC 1334 5 yr colectomy rate at 8.8%
TP use within 33 mo of diagnosis associated with increased 
risk of colectomy
aTNF Sjöberg et al[24] Multi-centre retrospective 
analysis of IFX rescue 
therapy
Acute severe UC   211 64%, 59% and 53% colectomy-free survival at years 1, 3, 5
Majority of colectomies within first 2 wk of IFX therapy
Gustavsson et al[26] RCT comparing IFX rescue 
therapy vs placebo
Acute severe UC     45 3 yr colectomy free survival 50%
Laharie et al[29] Head to head RCT 
comparing IFX vs CSA as 
rescue therapy
Acute severe UC   115 No significant differences in colectomy rates between two 
therapies at 3 mo
Sandborn et al[19] ACT 1 and 2 RCT of IFX vs 
placebo
Moderate to 
severe UC
  728 Colectomy rate significantly lower in IFX group (10% vs 
17%) at 54 wk
Feagan et al[41] ULTRA 1 and 2 RCT of 
ADA vs placebo
Moderate to 
severe UC
  963 Very low colectomy rates reported at 52 wk (approximately 
4%)
No difference in colectomy rates between ADA and 
placebo
Reich et al[45] Time trends analysis of 
colectomy rates following 
introduction of IFX
Unselected UC   481 19% annual decrease in elective colectomy in biologic era
15% annual decrease in emergency colectomy in biologic 
era
Costa et al[50] Meta-analysis of aTNF use 
in UC
Moderate to 
severe UC
  836 Reduced risk of surgery at 1 yr in patient treated with IFX 
compared to placebo (OR = 0.55)
NNT was 11
UC: Ulcerative colitis; aTNF: Tumour necrosis factor inhibitors; RCT: Randomised controlled trial; AZA: Azathioprine; TP: Thiopurine; 5-ASA: 
5-aminosalicylic acid; IFX: Infliximab; CSA: Ciclosporin; ADA: Adalimumab; NNT: Number needed to treat; N/A: Not applicable; ACT: Active ulcerative 
colitis trials; ULTRA: Ulcerative colitis long-term remission and maintenance with adalimumab.
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arms, making interpretation of this study difficult[26]. Of 
particular note, mucosal healing at 3 mo was strongly 
inversely related to the need for colectomy, with a 
colectomy rate of 0% in those who achieved mucosal 
healing at 3 mo, compared to 50% in patient who 
did not. The importance of achieving mucosal healing 
with respect to reducing the need for colectomy in UC 
patients treated with IFX has been further highlighted 
in a number of other studies including a sub­analysis of 
the original ACT trials[27,28].
The available evidence suggests a protective effect 
of aTNFs in reducing colectomy rates in patients with 
acute severe UC in the short­term. However, this effect 
does not appear to be superior to “rescue” therapy with 
ciclosporin. The results of the CYSIF trial, a randomised 
open labelled trial comparing ciclosporin vs IFX in 115 
patients with acute severe UC (who failed to respond 
to 5 d of intravenous corticosteroid therapy), showed 
no significant differences in colectomy free survival at 
98 d in either group (25.9% vs 26.3% respectively)[29]. 
In contrast, results from the United Kingdom national 
IBD audit indicated a significantly higher emergency 
colectomy rate in acute severe UC patients “rescued” 
with ciclosporin compared to IFX (35% vs 19%), 
although only colectomies performed in the same index 
admission were considered and may reflect selection 
bias[30]. Meta­analyses on this subject have not esta­
blished superiority of either therapy in the context of 
acute severe UC[31,32]. Moreover, Laharie et al[33] has 
recently presented (in abstract) the long­term follow 
up data from the original CYSIF trial participants 
that indicates no significant differences in long­term 
colectomy­free survival between ciclosporin and IFX (5 
years colectomy­free survival 61% ± 7% in ciclosporin 
group vs 65% ± 7% in IFX group)[33]. The full analysis 
is awaited, along with the findings of CONSTRUCT, a 
United Kingdom based trial on the same topic[34].
Moderate to severe UC: The term moderate­to­
severe UC includes a heterogenous population of colitic 
patients including steroid­dependent UC and steroid­
refractory UC, making comparison of studies more 
difficult. 
Following the ACT 1 and ACT 2 trials, a number 
of smaller uncontrolled single centre retrospective 
observational studies on the effect of aTNF therapy on 
colectomy rates beyond 6 mo have been published[35­38]. 
All had follow up periods of at least 12 mo. In these “real 
life” descriptions of aTNF use, there was considerable 
variation in the colectomy rates, from 2.7% at 42 mo 
to 53.3% at 12 mo. However, patient numbers in these 
studies were limited and there was significant disparity 
in patient demographics, disease extent, and severity. 
Reinisch et al[39] published the results of the extension 
study from the original ACT trials in 2012. Patients who 
had achieved benefit from IFX in ACT 1/2, were offered 
a further 3 years of treatment. Those on 5 mg/kg doses 
had the option to increase the dose to 10 mg/kg if the 
investigators felt response had been lost. From 229 
surgical short­term measures as primary outcomes. 
Longitudinal population based data is possibly more 
supportive of the protective role of thiopurine therapy 
against colectomy, and sufficient exposures may be 
required to reduce this risk, but this might not be 
always possible in patients with an early onset severe 
disease phenotype.
aTNF therapy and long-term surgical outcomes
The Active Ulcerative Colitis Trials (ACT 1 and ACT 
2) published in 2005 by Rutgeerts et al[8] showed 
the potential benefit vs placebo of the aTNF agent, 
infliximab (IFX), on clinical and endoscopic responses in 
728 outpatients with moderate­to­severe UC. Colectomy 
data from this cohort was later reported in 2009[19]. The 
analysis indicated a cumulative incidence of colectomy 
of 10% in the IFX group compared to 17% in the 
placebo group (HR of 0.59, 95%CI: 0.38­0.91) pointing 
to a protective effect against colectomy. However, the 
median follow up was only 6.2 mo and there was a 
significant study drop­out rate, nor was the indication 
for colectomy clearly defined. In contrast, a placebo­
controlled study by Järnerot et al[20] in 2005 looking at 
IFX therapy in 45 patients with fulminant UC reported 
a 29% colectomy rate in the treated arm at the end of 
the trial (90 d) vs 67% in the placebo arm[20]. The wide 
discrepancy in colectomy rates between the 2 studies 
reflects differing patient subtypes enrolled in both trials, 
namely chronic non­acute severe cases vs acute severe 
colitis patients, and this is considered further below.
Acute severe UC: Several small retrospective single 
centre observational studies exist recording colectomy 
rates following aTNF treatment in acute severe UC[21­23]. 
Colectomy was required in 37%­53% of patients, 
although there was considerable heterogeneity in the 
patient subgroups and follow up periods (6­22 mo) 
between the different studies. A large Swedish multi­
centre retrospective analysis of 211 aTNF­naive patients 
with acute severe UC treated with 5 mg/kg IFX as 
“rescue” therapy reported colectomy free survivals of 
64%, 59% and 53% at years 1, 3 and 5 suggesting a 
considerable long term protection against colectomy in 
this group of patients[24]. However, in this study 64% 
of all the colectomies (i.e., IFX failures) in the first year 
occurred within the first 2 wk possibly suggesting a sub 
group of patients with more severe disease in whom IFX 
cannot alter risk of colectomy. More recently, accelerated 
aTNF induction regimes have been shown to reduce very 
early colectomy in acute severe UC, although long­term 
colectomy free survival does not appear to be improved 
with this strategy[25]. 
Gustavsson et al[26] prospectively reported similar 
3 years colectomy­free survival rates of 50% in the 
treated arm of the original 45 patients with acute 
severe UC entered into an earlier RCT by Järnerot et 
al[20], although some patients had further IFX rescue 
treatments in follow up and there were differing rates 
of immuno­modulator use in the treatment and placebo 
Alexakis C et al . Thiopurines and aTNF therapy on outcomes in UC
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patients accepted into the 3 year extension study, there 
were only 2 colectomies (< 1%). This result should be 
treated with caution regarding the long­term benefits of 
aTNF therapy since it can be argued that those patients 
who survived without colectomy beyond the early 
stages of diagnosis have inherently less aggressive 
disease. Secondly, by virtue of their early response in 
ACT 1 and 2, these patients may have more responsive 
disease. Additionally, up to half of the original ACT 1 and 
2 patients in the treatment arm were also on immuno­
modulator therapy, which may have provided additional 
benefit in reducing the need for colectomy.
The ULTRA 1 and ULTRA 2 trials were randomised 
placebo controlled trials of Adalimumab (ADA) for the 
induction and maintenance of remission in moderate 
to severe UC[9,40]. In 2014, Feagan et al[41] published 
the hospitalisation and surgical outcomes from this 
cohort. Interestingly, no differences in the colectomy 
rates between treatment and placebo arm during the 
52 wk follow up was found. However, overall reported 
colectomy rates were only 4%­5%, and the authors 
acknowledged that this surprisingly low rate meant the 
study was insufficiently powered to assess for differences 
in surgical outcomes. Again there was a large proportion 
of patients on concomitant immuno­modulator therapy 
in both treatment and placebo arms (37% vs 35%). 
In a subsequent meta­analysis of 5 RCTs comparing 
ADA or IFX against placebo (including both ACT and 
ULTRA trials), both were equally efficacious in achieving 
clinical remission at 52 wk compared to placebo, but 
unfortunately no colectomy data was considered in the 
comparison[42].
In a retrospective study of 48 Spanish ENEIDA 
registry patients with either steroid dependent UC or 
steroid refractory UC treated with ADA, colectomy 
rates were reported at 22.9% after a mean of 205 d[43]. 
Clinical response was determined using the Mayo/partial 
Mayo scores at week 12, 28 and 54. The only predictor 
of colectomy was failure to respond to ADA at week 12. 
However, it was noted by the researchers that there 
was a high variation of co­medication with other IBD 
drugs, and that 81% of the cohort had already tried IFX 
prior to their induction with ADA.
A number of researchers have attempted to deter­
mine whether the use of aTNF therapies may alter 
surgical outcomes using epidemiological methods. 
Cannom et al[44] used United States Nationwide 
Inpatient Sample data combined with census data 
to estimate surgical rates in the 7 years following the 
Food and Drug Administration approval for IFX in IBD. 
No downward trend in surgery was seen over the 
study period of 1998­2005 in either Crohn’s disease or 
UC, but arguably it was too early to see a noticeable 
effect of IFX on surgical rates over this relatively short 
period. Reich et al[45] performed a time­trends study of 
colectomy incidence rates in a Canadian subpopulation 
of UC patients before and after the approval of IFX for 
UC treatment in 2005. In the biologic era, the annual 
percentage of both emergency and elective colectomy 
rates fell: 18.6% (95%CI: 13.8%­23.3%) and 14.9% 
(95%CI: 2.18%­25.8%) respectively. This occurred 
during a period of rapid increase in the proportion of 
IFX use and no proportional changes in the use of 
other IBD medications. A relationship between the two 
was inferred, but the authors accept there may have 
been other changes in management that could have 
contributed to declining colectomy rates over this time. 
Most recently, preliminary data from a very large United 
States cohort of almost 400000 UC patients admitted 
to hospital between 1998 and 2011 showed no change 
in colectomy rates in the era before and after the 
introduction of aTNF[46]. 
Meta­analyses on the subject have helped clarify 
the clinical question. Recently, Lopez et al[47] performed 
a meta­analysis of 5 placebo controlled RCTs[8,9,40,48,49] 
assessing efficacy of a variety of aTNF therapies 
including IFX, ADA and Golimumab in patients with 
moderate to severe UC. The authors concluded that 
treatment with aTNF was superior to placebo in 
achieving the primary endpoints (maintaining remission 
and achieving mucosal healing), but only IFX had any 
effect on reducing colectomy rates. However, only 2 
studies[19,41] were included in the analysis of surgery. 
In overall analysis of both studies, aTNF therapy was 
not more effective than placebo in reducing the risk of 
colectomy (RR = 0.87, 95%CI: 0.42­1.81). In subgroup 
analysis, IFX was superior to placebo in reducing the 
need for colectomy (RR = 0.64, 95%CI: 0.43­0.97) 
although follow up was limited to only 6.2 mo. A similar 
protective effect was not seen for ADA.
An earlier systematic review and meta­analysis of 
27 IBD studies was published in 2013 by Costa et al[50], 
and included data for 836 UC patients treated with IFX 
only. Pooled results from 4 RCTs with follow up ranging 
from 6 to 156 wk (including 3 studies not assessed in 
the meta­analysis by Lopez) suggested a reduced risk of 
surgery with IFX (pooled OR = 0.55, 95%CI: 0.40­0.76, 
number needed to treat = 11)[19,26,51,52]. However, the 
analysis was very heavily dependent on the findings 
from ACT 1 and 2 follow up (91% weighted), and 
furthermore, a similar protection against colectomy 
was not seen in the pooled data from the observational 
studies (although there was considerable heterogeneity 
in these studies).
In summary, whilst there appears to be a clear 
benefit of aTNF in inducing clinical remission and 
achieving mucosal healing in UC patients in the short 
term, whether this is translated to long­term reduction 
in surgical risk is less apparent, and data is lacking. 
Available studies are limited, follow up is short, and 
patient populations are heterogenous. Similarly, popu­
lation based studies are also conflicted regarding the 
role of aTNF therapy in altering the long­term risk of 
colectomy. No data is available regarding the long term 
benefits of Golimumab in this respect. 
Physicians must also consider the potential detri­
mental side of aTNF use in this patient group, notably 
the possible impact of these medications on post­
Alexakis C et al . Thiopurines and aTNF therapy on outcomes in UC
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operative complications and/or mortality. In a large 
study by Ellis et al[53], post­colectomy mortality rates 
increased significantly between the era before and after 
the introduction of aTNF use in UC. A recent systematic 
review suggested increased post­operative complications 
in patients with Crohn’s disease on aTNF therapy[54]. 
However, data from other smaller UC cohorts have not 
indicated similar findings in patients treated with these 
agents[55].
Clearly, further work into the long­term protective 
role of aTNF drugs is required. Equally, the additional 
benefit of co­administration of TPs with aTNF therapy 
remains largely unexplored. Recent studies addressing 
this have not shown any additional protection against 
colectomy, but this strategy warrants further investi­
gation in the future[56].
HOSPITALISATION
The overall rate of hospitalisation in UC appears to 
be decreasing. Data from recent population based 
longitudinal studies indicate a declining trend in UC 
related admissions[57,58], although this is not universally 
reported in all populations[59,60]. A variety of environ­
mental, demographic and clinical parameters have been 
implicated as potential risk factors for hospitalisation in 
patients with UC, although studies into the impact of 
specific medications on this outcomes are limited. Table 
2 summarises the key research in this area.
Thiopurines and hospitalisation
Data regarding the impact of thiopurine use on the risk 
of hospitalisation is limited. A small retrospective study 
of 17 patients with severe UC assessed the frequency 
of admission to hospital before and after the initiation 
of AZA[61]. Analysis showed a significant decrease in the 
number of hospital admissions from a mean of 2.12 
± 0.69 in the preceding 4.2 ± 4.3 years to a mean of 
0.12 ± 0.33 in the following 5.8 ± 2.5 years (P = 0.000) 
after initiation of AZA. However, numbers were very 
small, and 14 of the subjects were also treated with 
ciclosporin to achieve remission at the time of induction 
with AZA. A large study from the United States Kaiser 
Permanente healthcare database between 1998­2005 
reported trends in medication use and a variety of key 
outcomes in a cohort of 5895 UC patients[62]. Over the 
study period, immuno­modulator therapy in UC patients 
increased by 150% (steroid and 5­aminosalicylic acid 
use also increased over this period but to a much less 
extent). Over the same period acute hospital admissions 
were reduced by almost a third. A relationship between 
these two findings can only be made by inference. 
However, as the study was performed in an era before 
United States approval of aTNF agents in UC, there is 
no confounding by this medication group.
Most recently, Vester­Andersen et al[63] published 
the hospitalisation rates of a Danish inception cohort of 
IBD patients including (300 patients with UC) between 
2003 and 2011. Forty­seven percent of the UC cohort 
Table 2  Summary of key research investigating impact of thiopurines and tumour necrosis factor inhibitors therapy on 
hospitalisation in ulcerative colitis
Ref. Study design Population n Key findings
Thiopurines Actis et al[61] Retrospective study 
comparing hospitalisation 
before and after AZA 
induction
Severe UC     17 Significant decrease in hospitalisation for patients with UC up 
to 5.8 yr following AZA induction
Most of patients were also treated with ciclosporin at AZA 
induction
Herrinton et al[62] Population based cohort 
study of prescribing trends 
in UC
Unselected 
UC
5895 150% increase in immuno-modulator use in UC between 
1998-2005
Concurrent reduction in UC hospitalisations in the same period 
by a third
Vester-Andersen et al[63] Prospective descriptive study 
of IBD inception cohort
Unselected 
UC
  300 26% exposure to immuno-modulator during follow up
Hospitalisation rates decreased from 4.7 d/person-years in year 
1 after diagnosis to 0.4 d in year 5
Immuno-modulator therapy found not to be significant in 
predicting need for hospitalisation
aTNF Carter et al[65] Medical insurance cost 
analysis study
Unselected 
UC
  420 UC patients with a prescription for infliximab for > 80% of 
the study period had less hospitalisation requirement, lower 
admission costs and shorter inpatient stays
Oussalah et al[37] Multicentre retrospective 
study on outcomes in UC 
patients post aTNF
Unselected 
UC
  191 Estimated hospitalisation-free survival at 1, 2, 3 and 6 yr were 
66.7%, 60.2%, 57.1% and 44.6% respectively
Earlier use of aTNF predictive of need for hospitalisation
Sandborn et al[19] ACT 1 and 2 RCT comparing 
IFX with placebo
Moderate to 
severe UC
  728 Of patients treated with IFX, 84% remained free of 
hospitalisation at 54 wk, compared to 75% in the placebo group
Feagan et al[41] ULTRA 1 and 2 RCT 
comparing ADA with 
placebo
Moderate to 
severe UC
  963 Significantly reduced all-cause and UC-related admissions at 
both 8 wk and 52 wk in patients treated with ADA compared to 
placebo
Lopez et al[47] Meta-analysis of aTNF in UC 
outcomes
Moderate to 
severe UC
  964 aTNF therapy was superior to placebo in reducing UC-related 
hospitalisations, with a relative risk of 0.71 (95%CI: 0.56-0.90)
UC: Ulcerative colitis; aTNF: Tumour necrosis factor inhibitors; RCT: Randomised controlled tria; AZA: Azathioprine; IFX: Infliximab; ADA: Adalimumab; 
IBD: Inflammatory bowel disease; ACT: Active ulcerative colitis trials; ULTRA: Ulcerative colitis long-term remission and maintenance with adalimumab.
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had at least one admission to hospital over the follow 
up period, and admission rates decreased from 4.7 d/
person­years in year 1 after diagnosis to 0.4 d in year 
5. Twenty six percent of UC had exposure to immuno­
modulator therapy in follow up with a median time to 
exposure of 433 d from diagnosis. In a sub­analysis, 
however, immuno­modulator exposure was not found to 
be significant in predicting the need for hospitalisation.
In summary, data is lacking to suggest with certainty 
that immuno­modulator therapy has a role in avoiding 
hospitalisation in UC. 
aTNF therapy and hospitalisation
The cost of biologic therapy has dramatically shifted 
the overall healthcare costs in IBD. The recent Dutch 
COIN study sought to estimate the expenditure of 
medications, treatments and hospitalisation of large 
cohort of adult IBD patients including 937 UC patients[64]. 
The biggest cost driver was medication, notably aTNFs, 
with hospitalization and surgery accounting for 19% and 
< 1% respectively of total costs. Hospitalisation remains 
costly for healthcare providers, and if medical therapy 
can reduce the need for admission, this can potentially 
offset the cost of expensive treatments. 
Relatively few retrospective observational studies 
have looked at hospitalisation rates with respect to aTNF 
use in UC. Carter et al[65] published the results of a cost 
analysis based on 420 UC patients’ medical insurance 
claims for IFX treatment in relation to hospitalisation 
and admission costs. In a sub­analysis whereby patients 
were categorised by persistent IFX use (defined as 
having a prescription of IFX > 80% of the time), patients 
with “persistent” maintenance therapy had less hospi­
talisation (3% vs 20.4%), lower inpatient costs, and 
shorter inpatient stays.
In a French multi­centre retrospective analysis of 
191 unselected UC patients with varied severity treated 
with IFX, 36.1% of patients required at least one 
admission during follow up[37]. Estimated hospitalisation­
free survival at 1, 2, 3 and 6 years were 66.7%, 60.2%, 
57.1% and 44.6% respectively. Earlier time from 
diagnosis to IFX treatment was strongly predictive of 
need for first hospitalisation. Conversely, a small study 
from Hungary showed no change in hospitalisation 
rates in UC patients following the introduction of IFX 
treatment compared to the pre­IFX era[66]. 
A follow up study to ACT 1 and 2 also examined 
hospitalisation rates[19]. In the treatment arm, 84% 
remained free of hospitalisation at 54 wk, compared to 
75% in the placebo group. The proportion of patients 
requiring 1, 2 or more than 2 UC­related admissions was 
also significantly higher in the placebo group. Similarly, 
findings from ULTRA study also reported significantly 
reduced all­cause and UC­related admissions at both 8 
wk and 52 wk in patients treated with ADA compared to 
placebo[41].
Two meta­analyses have evaluated the impact of 
aTNFs on rates of hospitalisation[49,50]. A sub­analysis of 
hospitalisation by Lopez et al[49], included 964 UC patients 
receiving aTNF derived from two RCTs with follow up 
between 52 and 54 wk. aTNF therapy was superior to 
placebo in reducing UC­related hospitalisations, with a 
relative risk of 0.71 (95%CI: 0.56­0.90). In a separate 
analysis, both IFX and ADA were found to be effective 
in reducing UC­related hospitalisations, with a number 
needed to treat of 18 (95%CI: 9­911) and 23 (95%CI: 
12­506) respectively. Costa et al[50] also found a 49% 
(OR 0.41, 95%CI: 0.40­0.65) reduction in risk of 
hospitalisation in UC patients treated with IFX compared 
to placebo in analysis of three RCTs not included in the 
study by Lopes.
In summary, aTNF agents appear to have a potential 
effect in reducing hospitalisation in patients with UC. 
Most research on hospitalisation focuses on early 
admission rates (under a year). There is clear need to 
further evaluate the impact of these medications on 
hospitalisation in the longer term. 
CONCLUSION
Thiopurines and aTNF therapy form a key part of 
treatment in patients with UC. Both have established 
roles in the induction and maintenance of remission. Their 
role in altering the long­term requirement of surgery and 
hospitalisation is less clear. Whilst 5 years surgery rates 
have reduced in Crohn’s disease, they remain essentially 
unchanged in UC[1]. Thiopurines appear to have a long­
term benefit in reducing the need for surgery in UC, 
although there is a subgroup of UC patients who do not 
derive benefit from these medications, and require early 
colectomy. Whereas IFX reduces the need for surgery in 
the short­term, the evidence that aTNF agents alter the 
long­term requirement of colectomy is again limited.
The role of thiopuriness and aTNFs in reducing 
hospitalisation is more difficult to interpret in the context 
of differing models of healthcare provision and changes 
in other aspects of UC management. However, overall 
the evidence generally supports their respective roles 
in reducing acute admissions. Further work is required 
to evaluate the important question of the long­term 
benefits of medical therapy on reducing the requirement 
of for surgery and hospitalisation in UC.
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